ISNES, Belgium, Sept. 22, 2017 /PRNewswire/ -- VolitionRx
Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its
strategy for a new range of Clinical Research Use Only (RUO) kits
based on its proprietary Nucleosomics™ technology and the
receipt of an order of RUO kits from a large multinational
pharmaceutical company.
Chief Executive Officer of Volition, Cameron Reynolds, commented, "This is a very
important milestone for Volition as it represents our first revenue
from the Nu.Q™ platform. The RUO kits could be used to develop
a companion diagnostic to a pharmaceutical company's therapeutic
product, so could represent an additional potential revenue stream
beyond the commercialization of our blood-based cancer tests on the
same platform of assays. After the initial sale of the RUO kits, a
significant licensing arrangement is possible if the assays become
a crucial component of another company's product."
The RUO kits use the same platform as Volition's cancer
diagnosis panels but may be used for many other purposes, for
example as an aid to drug development and treatment selection. This
first sale followed a request for a bespoke kit and precedes the
launch of the first series of Volition's products.
Volition aims to offer off-the-shelf kits initially with a
Total Nucleosome assay in the first quarter of 2018, followed in
the second quarter of 2018 by a range of kits initially developed
for its own internal cancer diagnostic development programs. The
RUO range will allow researchers to explore patterns of epigenetic
modifications in circulating nucleosomes across a broad range of
clinical applications including cancers, inflammatory and
infectious diseases.
Dr. Mark Eccleston, Volition's
Business Development Director, commented, "There has been a lot of
interest in collaborating with Volition for evaluating nucleosome
profiles in a range of applications beyond our core focus in
diagnostics. Our suite of Nu.Q™ RUO assays will
provide researchers with a complete solution for profiling cell
free nucleosomes from cell to serum. This will raise the profile of
our approach and broaden the application base beyond our current
focus in cancer. The RUO kits will provide external validation of
our technology and an expanded user base. We expect this to lead to
future licensing opportunities from new clinical applications of
our Nucleosomics™ technology."
About Volition
Volition is a multi-national life sciences company developing
simple, easy to use blood-based cancer tests to accurately diagnose
a range of cancers. The tests are based on the science of
Nucleosomics®, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid - an
indication that disease is present.
As cancer screening programs become more widespread, Volition's
products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life.
Volition's research and development activities are currently
centered in Belgium, with
additional offices in London,
Texas and Singapore, as the
company focuses on bringing its diagnostic products to market first
in Europe, then in the U.S. and
ultimately, worldwide.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Day,
Volition
L.day@volitionrx.com
+44 (0)7557
774620
|
Scott Powell,
Volition
S.powell@volitionrx.com
+1 (646) 650
1351
|
Tirth Patel,
Edison Advisors
tpatel@edisongroup.com
+1 (646) 653
7035
|
Rachel Carroll,
Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077
5711
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the effectiveness of Volition's bodily-fluid-based diagnostic
tests as well as Volition's ability to develop and successfully
commercialize such test platforms for early detection of cancer.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties. For instance, if Volition fails to develop and
commercialize diagnostic products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products in the clinical
IVD market; a failure by the marketplace to accept the products in
Volition's development pipeline or any other diagnostic products
Volition might develop; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics market and its rapid
technological change; and other risks identified in Volition's most
recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as other documents that Volition files with the
Securities and Exchange Commission. These statements are based on
current expectations, estimates and projections about Volition's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics®, NuQ®, Nu.Q™ and HyperGenomics® and their
respective logos are trademarks and/or service marks of VolitionRx
Limited and its subsidiaries. All other trademarks, service marks
and trade names referred to in this press release are the property
of their respective owners. Additionally, unless otherwise
specified, all references to "$" refer to the legal currency of
the United States of America.
View original
content:http://www.prnewswire.com/news-releases/volitionrx-announces-the-initial-sale-of-its-new-nuqtm-research-kits-300524296.html
SOURCE VolitionRx Ltd